XML 95 R54.htm IDEA: XBRL DOCUMENT v3.25.0.1
Restructuring (Tables)
12 Months Ended
Dec. 29, 2024
Restructuring and Related Activities [Abstract]  
Summary of Severance Charges and Associated Spending
The following table summarizes the restructuring expenses for the fiscal years 2024 and 2023:
(Pre-tax Dollars in Millions)20242023
Innovative Medicine Segment(1)
$102479
MedTech Segment(2)
167319
Total Programs$269$798
(1)The fiscal year of 2024 included $102 million in Restructuring on the Consolidated Statement of Earnings. The fiscal year of 2023 included $449 million in Restructuring and $30 million in Cost of products sold on the Consolidated Statement of Earnings.
(2)The fiscal year of 2024 included $132 million in Restructuring and $35 million in Cost of products sold on the Consolidated Statement of Earnings. The fiscal year of 2023 Included $40 million in Restructuring and $279 million in Cost of products sold on the Consolidated Statement of Earnings.